Approach to the treatment of patient with T2-associated bronchial asthma using biological therapy: a case report from real practice
- Authors: Peredelskaya M.Y.1, Sebekina O.V1, Nenasheva N.M1, Peredelsky Y.A2
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- Bryansk City Hospital № 4
- Issue: Vol 28, No 5 (2021)
- Pages: 127-130
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313155
- DOI: https://doi.org/10.18565/pharmateca.2021.5.127-135
- ID: 313155
Cite item
Open Access
Access granted
Abstract
Background. This article is devoted to the description of T2-associated bronchial asthma (BA), the role of the main cytokines that form T2-inflammation. The emphasis on the participation of interleukins 4 and 13 as key cytokines in the initiation and maintenance of T2 inflammation in the pathogenesis of BA is made. Description of the clinical case. The article presents a clinical case with the selection of a biological drug and further long-term and effective use of a biological molecule - dupilumab for the treatment and control of severe T2-associated asthma. Conclusion. In the case of our patient, dupilumab significantly improved the control of severe asthma; there were no exacerbations or episodes of taking systemic glucocorticosteroids. The most significant effect for the patient was an increase in the psycho-emotional background, an increase in physical and social activity and, as a result, an improvement in the quality of life.
Full Text
About the authors
Marina Yu. Peredelskaya
Russian Medical Academy of Continuous Professional Education
Email: concy1984@gmail.com
Teaching Assistant at the Department of Allergology and Immunology Moscow, Russia
O. V Sebekina
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
N. M Nenasheva
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
Yu. A Peredelsky
Bryansk City Hospital № 4Bryansk, Russia
References
- Croisant S. Epidemiology of asthma: prevalence and burden of disease. Adv Exp Med Biol. 2014;795:17-29. doi: 10.1007/978-1-4614-8603-9_2
- Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. М.: Российское респираторное общество, Российская ассоциация аллергологов и клинических иммунологов; 2019. Доступно на: http://spulmo.ru/obrazovatelnye-resursy/ federalnye-klinicheskie-rekomendatsii/ (дата обращения: 06.03.21).
- GINA v2.0 2019 Difficult-to-Treat & Severe Asthma in adolescent and adult patients: Diagnosis and management. A GINA Pocket Guide for Health Professionals. Available at: https://ginasthma.org/ wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf (date accessed: 15 апреля 2021).
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2020. Available at: https://ginasthma.org/gina-report (date accessed: 06.03.21).
- Agache I., Akdis C.A. Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. Allergol Int. 2016;65(3):243-52. Doi: 10.1016/j. alit.2016.04.011.
- Сергеева Г.Р., Емельянов А.В., Коровина О.В. и др. Тяжелая бронхиальная астма: характеристика пациентов в клинической практике. Терапевтический архив. 2015;87(12):22-7.
- Abbas A.K., Lichtman A.H., Pillai S. Cellular and Molecular Immunology 9th еd. Elsevier, 2018. 608 р. Available at: https://www.elsevier.com/ books/cellular-and-molecular-immunology/ abbas/978-0-323-47978-3.
- Gandhi N.A., Pirozzi G., Graham N.M.H. Commonality of the IL-4/IL-13pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425-37. doi: 10.1080/1744666X.2017.1298443.
- Matsunaga K., Katoh N., Fujieda S., et al. Dupilumab: Basic aspects and applications to allergic diseases. Allergol Int. 2020;69(2):187-doi: 10.1016/j.alit.2020.01.002.
- Ненашева Н.М. Т2-бронхиальная астма: характеристика эндотипа и биомаркеры. Пульмонология. 2019;29(2):216-28.@@Nenasheva N.M. T2-high and T2-low bronchial asthma, endotype characteristics and biomarkers. Pulmonologiya. 2019;29(2):216-28. doi: 10.18093/0869-0189-2019-29-2-216-228. (In Russ.).
- Gandhi N.A., Bennett B.L., Graham N.M., et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50. doi: 10.1038/nrd4624.
- Castro M., Corren J., Pavord I.D., et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486-96. Doi: 10.1056/ NEJMoa1804092.
- Rabe K.F., Nair F.I., Brusselle G., et al. Efficacy and safety of dupilumab in glucocorticoiddependent severe asthma. N Engl J Med. 2018;378(26):2475-85. Doi: 10.1056/ NEJMoa1804093.
- Bourdin A., Fabry-Vendrand C., Ostinelli J., et al. The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database. J Allergy Clin Immunol Pract. 2019;7(5):1477-87. doi: 10.1016/j.jaip.2018.12.029.
- Agache I., Akdis C., Akdis M., et al. EAACI Biologicals Guidelines - Recommendations for severe asthma. Allergy. 2020:1-31. doi: 10.1111/all.14425.
- Webb D.C., McKenzie A.N.J., Koskinen A.M.L., et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol. 2000;165:108-13. Doi: 10.4049/ jimmunol.165.1.108.
- Wollenberg A., Beck L.A., Blauvelt A., et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120-35. Doi: 10.1111/ bjd.18434.
Supplementary files
